載入中
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
前收盤價
US$0.2894
+US$0.0009 · +0.31%
盤前
US$0.2894
US$0.00 · 0.00%
10月8日 上午4:09 ET
盤中時間採用ET。市場資料可能有所延遲。
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
日內區間
目前US$0.2894
52週區間
目前US$0.2894
盤中時間採用ET。市場資料可能有所延遲。
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
日內區間
目前US$0.2894
52週區間
目前US$0.2894
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 248.91萬 USD | 395.46萬 USD | — | 8.15萬 USD | 38.55萬 USD |
| 銷貨成本 | 1812.15萬 USD | 9.54萬 USD | 2072.08萬 USD | 912.35萬 USD | 1555.42萬 USD |
| 毛利 | −1563.24萬 USD | 385.92萬 USD | −2072.08萬 USD | −904.2萬 USD | −1516.87萬 USD |
| 研究與開發 | 1812.15萬 USD | 2371.36萬 USD | 2072.08萬 USD | 912.35萬 USD | 1555.42萬 USD |
| 銷售、一般及管理費用 | 600.67萬 USD | 538.53萬 USD | 594.8萬 USD | 498.66萬 USD | 357.72萬 USD |
| 營業費用 | 600.67萬 USD | 2900.35萬 USD | 602.22萬 USD | 498.66萬 USD | 357.72萬 USD |
| 利息收入 | 17.43萬 USD | 17.34萬 USD | 77.62萬 USD | 7439 USD | 4736 USD |
| 利息支出 | — | 2.14萬 USD | — | — | 1286 USD |
| 折舊和攤銷 | 6.88萬 USD | 9.54萬 USD | 7.42萬 USD | 5.63萬 USD | 3.85萬 USD |
| 營業利益 | −2163.9萬 USD | −2514.43萬 USD | −2674.29萬 USD | −1402.86萬 USD | −1874.58萬 USD |
| 淨利 | −2146.48萬 USD | −2499.23萬 USD | −2596.68萬 USD | −1402.11萬 USD | −1857.03萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月12日 | 1:25 | — | — |
股票分割 | 2024年1月31日 | 1:15 | — | — |
股票分割 | 2020年9月25日 | 1:20 | — | — |
股票分割 | 2020年1月24日 | 1:2,000 | — | — |
股票分割 | 2019年5月2日 | 1:500 | — | — |
股票分割 | 2010年4月28日 | 1:50 | — | — |
已生效 2026年1月12日
1:25
已生效 2024年1月31日
1:15
已生效 2020年9月25日
1:20
已生效 2020年1月24日
1:2,000
已生效 2019年5月2日
1:500
已生效 2010年4月28日
1:50
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
